Karyopharm Therapeutics Inc. KPTI
We are a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer. Our scientific expertise is based upon an understanding of the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 ("XPO1"). These compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases with high unmet medical need. Our lead asset, XPOVIO® (selinexor), was the first oral XPO1 inhibitor to receive marketing approval, receiving its initial U.S. approval from the U.S. Food and Drug Administration ("FDA") in July 2019, and is currently approved and marketed in the U.S. for the following indications:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M | $108.1M | $40.9M | $30.3M | $1.6M | $154.0K |
| R&D | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M | $150.8M | $122.3M | $161.4M | $107.3M | $86.9M |
| SG&A | $105.2M | $115.4M | $131.9M | $145.4M | $143.8M | $126.4M | $105.4M | $48.8M | $24.9M | $23.9M |
| Total operating expenses | $236.8M | $264.7M | $275.6M | $299.3M | $308.1M | $279.9M | $230.2M | $210.2M | $132.1M | $110.9M |
| Operating income | -$90.7M | -$119.4M | -$129.5M | -$142.2M | -$98.3M | -$171.8M | -$189.3M | -$179.9M | -$130.5M | -$110.7M |
| Interest expense | $45.8M | $37.4M | $23.8M | $25.0M | $26.0M | $27.1M | $15.6M | $2.5M | — | — |
| Pre-tax income | -$196.0M | -$76.4M | -$142.8M | -$164.9M | -$123.8M | -$196.0M | -$199.6M | -$178.4M | -$128.9M | -$109.4M |
| Income tax | $43.0K | $57.0K | $323.0K | $369.0K | $268.0K | $309.0K | $40.0K | $26.0K | $63.0K | $139.0K |
| Net income | -$196.0M | -$76.4M | -$143.1M | -$165.3M | -$124.1M | -$196.3M | -$199.6M | -$178.4M | -$129.0M | -$109.6M |
| EPS, basic | -17.93 | -9.41 | -18.79 | -2.02 | -1.65 | -2.72 | — | — | — | — |
| EPS, diluted | -17.93 | -14.00 | -18.79 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 |
| Shares, diluted (wtd. avg.) | 10,935 | 8,455 | 7,616 | 81,871 | 75.2M | 72.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $60.5M | $62.5M | $52.2M | $136.9M | $197.4M | $89.1M | $130.7M | $118.7M | $69.5M | $50.1M |
| Short-term investments | $3.2M | $46.2M | $139.2M | $142.8M | $38.2M | $163.3M | $133.1M | $210.2M | $77.5M | $79.9M |
| Receivables | $26.2M | $30.8M | $27.0M | $47.1M | $22.5M | $12.9M | $7.9M | — | — | — |
| Inventory | $4.0M | $4.7M | $3.0M | $4.2M | $4.1M | $2.6M | $346.0K | — | — | — |
| Total current assets | $103.1M | $156.5M | $233.9M | $350.2M | $275.6M | $276.5M | $278.6M | $334.6M | $148.4M | $131.6M |
| Property, plant and equipment | $104.0K | $400.0K | $606.0K | $1.1M | $1.6M | $2.2M | $3.0M | $3.9M | $2.2M | $2.8M |
| Total assets | $108.4M | $164.4M | $240.4M | $358.2M | $305.3M | $313.1M | $295.0M | $341.2M | $180.3M | $180.4M |
| Accounts payable | $4.0M | $5.1M | $3.1M | $2.8M | $1.6M | $4.5M | $985.0K | $4.3M | $5.7M | $4.8M |
| Total current liabilities | $92.1M | $92.3M | $69.5M | $65.9M | $73.7M | $60.2M | $46.4M | $46.9M | $49.5M | $16.5M |
| Long-term debt | — | — | — | — | $169.3M | — | — | — | — | — |
| Total liabilities | $401.3M | $350.4M | $376.6M | $374.8M | $385.0M | $262.5M | $245.2M | $158.0M | $50.8M | $18.1M |
| Retained earnings | -$1.76B | -$1.56B | -$1.49B | -$1.34B | -$1.18B | -$1.07B | -$873.3M | -$673.7M | -$495.3M | -$366.1M |
| Total equity | -$292.9M | -$186.0M | -$136.2M | -$16.7M | -$79.7M | $50.5M | $49.8M | $183.2M | $129.5M | $162.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.4M | -$127.5M | -$92.7M | -$149.6M | -$107.1M | -$160.2M | -$190.8M | -$159.1M | -$73.7M | -$84.4M |
| Depreciation and amortisation | $296.0K | $340.0K | $530.0K | $621.0K | $789.0K | $972.0K | $974.0K | $735.0K | — | — |
| Stock-based compensation | $14.1M | $18.4M | $21.7M | $35.4M | $29.8M | $24.4M | $15.3M | $17.3M | $20.4M | $22.3M |
| Capital expenditure | $0 | $142.0K | $0 | $118.0K | $212.0K | $145.0K | $206.0K | $2.4M | $62.0K | $70.0K |
| Investing cash flow | $43.4M | $95.5M | $7.9M | -$104.3M | $141.8M | -$53.7M | $78.5M | -$107.7M | $17.1M | $24.6M |
| Financing cash flow | $30.0M | $41.6M | $1.1M | $193.7M | $73.6M | $172.1M | $124.3M | $316.1M | $75.7M | $51.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001503802-26-000023.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $154.0K | $1.6M | $30.3M | $40.9M | $108.1M | $209.8M | $157.1M | $146.0M | $145.2M | $146.1M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$109.6M | -$129.0M | -$178.4M | -$199.6M | -$196.3M | -$124.1M | -$165.3M | -$143.1M | -$76.4M | -$196.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |